Review Article

You have full text access to this OnlineOpen article

A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance†

  1. Thorsten Kuehn M.D.1,‡,*,
  2. Andreas Bembenek M.D.2,
  3. Thomas Decker M.D.3,
  4. Dieter Ludwig Munz M.D.4,
  5. Marie-Luise Sautter-Bihl M.D.5,
  6. Michael Untch M.D.6,
  7. Diethelm Wallwiener M.D.7,
  8. For the Consensus Committee of the German Society of Senology§

Article first published online: 20 DEC 2004

DOI: 10.1002/cncr.20786

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 451–461, 1 February 2005

Additional Information

How to Cite

Kuehn, T., Bembenek, A., Decker, T., Munz, D. L., Sautter-Bihl, M.-L., Untch, M., Wallwiener, D. and For the Consensus Committee of the German Society of Senology (2005), A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer, 103: 451–461. doi: 10.1002/cncr.20786

Author Information

  1. 1

    Department of Gynecology and Obstetrics, Interdisciplinary Breast Center, Gifhorn, Germany

  2. 2

    Department of Surgery and Surgical Oncology, Charite, Robert-Roessle-Klinik im HELIOS-Klinikum, Berlin, Germany

  3. 3

    Department of Pathology, Breast Unit, HELIOS-Klinikum Berlin, Berlin, Germany

  4. 4

    Clinic for Nuclear Medicine, Charite-Berlin University Medicine, Charite Campus Mitte, Berlin, Germany

  5. 5

    Department of Radiooncology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany

  6. 6

    Department of Gynecology and Obstetrics, LMU München, München, Germany

  7. 7

    Department of Gynecology and Obstetrics, University of Tuebingen, Tuebingen, Germany

  1. ‡

    Fax: 011 (49) 5371871608

  2. §

    The consensus committee of the German Society of Senology was comprised of A. Bembenek (Department of Surgery and Surgical Oncology, Charite, Robert-Roessle-Klinik im HELIOS-Klinikum, Berlin), H. Buechels (Department of Plastic and Reconstructive Surgery, Klinikum Augsburg, Augsburg), T. Decker (Department of Pathology, Breast Unit, HELIOS-Klinikum, Berlin), J. Dunst (Department of Radiooncology, Martin-Luther-Universität Halle, Wittenberg), T. Kuehn (Department of Gynecology and Obstetrics, Interdisciplinary Breast Center, Gifhorn), U. Muellerleile (Department of Oncology, Krankenhaus Barmbeck, Hamburg), D. L. Munz (Clinic for Nuclear Medicine, Charite-Berlin University Medicine, Charite Campus Mitte and Charite Campus Virchow Klinikum, Berlin), H. Ostertag (Department of Gynecology and Obstetrics, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel); M. L. Sautter-Bihl (Department of Radiooncology, Städtisches Klinikum Karlsruhe, Karlsruhe), H. Schirrmeister (Department of Nuclear Medicine, University, Schleswig-Holstein, Campus Kiel, Kiel), A. H. Tulusan (Department of Gynecology, Klinikum Bayreuth, Bayreuth), M. Untch (Department of Gynecology and Obstetrics, LMU München, München), K. J. Winzer (Breast Center Charite, Berlin University Medecine, Campus Charite Mitte, Berlin), C. Wittekind (Institute of Pathology, University of Leipzig, Leipzig), and D. Wallwiener (Department of Gynecology and Obstetrics, University of Tuebingen, Tuebingen).

*Interdisziplinäres Brustzentrum, Frauenklinik, Bergstrsse 30, 38518 Gifhorn, Germany

  1. †

    See related editorial on pages 444–6, this issue.

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 20 DEC 2004
  3. Manuscript Accepted: 6 OCT 2004
  4. Manuscript Revised: 19 SEP 2004
  5. Manuscript Received: 15 JUL 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (111K)

REFERENCES

  • 1
    Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003; 21: 3357–3365.
  • 2
    SobinLH, WittekindC, editors. TNM classification of malignant tumors, 6th ed. New York: John Wiley & Sons, 2002.
  • 3
    GreeneFL, PageD, FlemingI, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.
  • 4
    Schwartz GF, Guiliano AE, Veronesi U. Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma or the breast April 19–22, 2001, Philadelphia, PA, USA. Breast J. 2002; 8: 124–138.
    Direct Link:
  • 5
    McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000; 18: 2560–2566.
  • 6
    Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med. 1998; 339: 941–946.
  • 7
    Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001; 233: 51–59.
  • 8
    Bergkvist L, Frisell J, Liljegren G, Celebioglu F, Damm S, Thorn M. Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br J Surg. 2001; 88: 1644–1648.
    Direct Link:
  • 9
    Kuehn T, Vogl FD, Helms G, et al. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol. 2004; 30: 252–259.
  • 10
    Roumen RM, Kuijt GP, Liem IH, van Beek MW. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg. 2001; 88: 1639–1643.
    Direct Link:
  • 11
    Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol. 2001; 77: 165–170.
    Direct Link:
  • 12
    Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000; 18: 2553–2559.
  • 13
    Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349: 546–553.
  • 14
    Morrow M, Rademaker AW, Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery. 1999; 126: 714–720.
  • 15
    Derossis AM, Fey J, Yeung H, et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg. 2001; 193: 473–478.
  • 16
    Cserni G. Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma. J Clin Pathol. 2002; 55: 293–297.
  • 17
    Heuser T, Rink T, Weller E, et al. Impact of the axillary nodal status on sentinel node mapping in breast cancer and its relevance for technical proceeding. Breast Cancer Res Treat. 2001; 67: 125–132.
  • 18
    Cox CE, Bass SS, Boulware D, Ku NK, Berman C, Reintgen DS. Implementation of new surgical technology: outcome measures for lymphatic mapping of breast carcinoma. Ann Surg Oncol. 1999; 6: 553–561.
  • 19
    Cody HS III, Hill AD, Tran KN, Brennan MF, Borgen PI. Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg. 1999; 229: 723–726.
  • 20
    McMasters KM, Wong SL, Chao C, et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg. 2001; 234: 292–299.
  • 21
    Sanidas EE, de Bree E, Tsiftsis DD. How many cases are enough for accreditation in sentinel lymph node biopsy in breast cancer? Am J Surg. 2003; 185: 202–210.
  • 22
    Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early-stage breast cancer. An analysis of 259 consecutive patients. Arch Surg. 1990; 125: 1144–1147.
  • 23
    Bader AA, Tio J, Petru E, et al. T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat. 2002; 76: 11–17.
  • 24
    Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985; 312: 674–681.
  • 25
    Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol. 2004; 22: 97–101.
  • 26
    Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg. 2000; 232: 81–89.
  • 27
    Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg. 1999; 229: 860–864.
  • 28
    Roumen RM, Geuskens LM, Valkenburg JG. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol. 1999; 25: 347–351.
  • 29
    Nathanson SD, Wachna DL, Gilman D, Karvelis K, Havstad S, Ferrara J. Pathways of lymphatic drainage from the breast. Ann Surg Oncol. 2001; 8: 837–843.
  • 30
    Maza S, Valencia R, Geworski L, et al. Peritumoural versus subareolar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: preliminary results of a prospective intra-individual comparative study. Eur J Nucl Med Mol Imaging. 2003; 30: 651–656.
  • 31
    Tanis PJ, Nieweg OE, Valdes Olmos RA, Kroon BB. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg. 2001; 192: 399–409.
  • 32
    Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003; 138: 309–313.
  • 33
    Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000; 18: 3480–3486.
  • 34
    Pendas S, Jakub J, Giuliano R, Gardner M, Swor GB, Reintgen DS. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control. 2004; 11: 231–235.
  • 35
    Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer. 2004; 100: 2512–2532.
    Direct Link:
  • 36
    McMasters KM, Wong SL, Tuttle TM, et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel nodes. Ann Surg. 2000; 231: 724–731.
  • 37
    McCarter MD, Yeung H, Fey J, Borgen PI, Cody HS III. The breast cancer patient with multiple sentinel nodes: when to stop? J Am Coll Surg. 2001; 192: 692–697.
  • 38
    Nieweg OE, Tanis PJ, Kroon BB. The definition of a sentinel node. Ann Surg Oncol. 2001; 8: 538–541.
  • 39
    Wong SL, Edwards MJ, Chao C, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001; 192: 684–689.
  • 40
    Kennedy RJ, Kollias J, Gill PG, Bochner M, Coventry BJ, Farshid G. Removal of two sentinel nodes accurately stages the axilla in breast cancer. Br J Surg. 2003; 90: 1349–1353.
    Direct Link:
  • 41
    Cserni G, Amendoeira I, Apostolikas N, et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer. 2003; 39: 1654–1667.
  • 42
    Cserni G. Axillary staging of breast cancer and the sentinel node. J Clin Pathol. 2000; 53: 733–741.
  • 43
    Cserni G. A model for determining the optimum histology of sentinel lymph nodes in breast cancer. J Clin Pathol. 2004; 57: 467–471.
  • 44
    Dowlatshahi K, Fan M, Anderson JM, Bloom KJ. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol. 2001; 8: 675–681.
  • 45
    Millis RR, Springall R, Lee AH, Ryder K, Rytina ER, Fentiman IS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer. 2002; 86: 396–401.
  • 46
    Farshid G, Pradhan M, Kollias J, Gill PG. Computer simulations of lymph node metastasis for optimizing the pathologic examination of sentinel lymph nodes in patients with breast carcinoma. Cancer. 2000; 89: 2527–2537.
    Direct Link:
  • 47
    Lacour J, Le MG, Hill C, Kramar A, Contesso G, Sarrazin D. Is it useful to remove internal mammary nodes in operable breast cancer? Eur J Surg Oncol. 1987; 13: 309–314.
  • 48
    Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999; 353: 1641–1648.
  • 49
    Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997; 337: 949–955.
  • 50
    Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997; 337: 956–962.
  • 51
    Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19: 1539–1569.
  • 52
    Sautter-Bihl ML, Hultenschmidt B, Melcher U, Ulmer HU. Radiotherapy of internal mammary lymph nodes in breast cancer. Principle considerations on the basis of dosimetric data. Strahlenther Onkol. 2002; 178: 18–24.
  • 53
    Kinne DW. Staging and follow-up of breast cancer patients. Cancer. 1991; 67: 1196–1198.
    Direct Link:
View Full Article (HTML) Get PDF (111K)